Back to top
more

Genmab (GNMSF)

(Delayed Data from OTC)

$274.35 USD

274.35
626

+4.48 (1.66%)

Updated Apr 26, 2024 03:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GNMSF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Genmab A/S [GNMSF]

Reports for Purchase

Showing records 1 - 20 ( 20 total )

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 1

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for GNMSF

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 2

04/18/2019

Company Report

Pages: 4

1Q19 DARZALEX Sales Cast Doubt on Guidance, as We Have Anticipated - We Estimate a 3.80 Q1 EPS; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 3

04/03/2019

Company Report

Pages: 4

We Are Optimistic Regarding a Rapid Approval Pathway for a DARZALEX plus Revlimid Maintenance Regimen; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 4

04/02/2019

Company Report

Pages: 4

Pivotal Phase 2 Tisotumab Vedotin Trial Enrollment Completion an Incremental Positive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 5

03/27/2019

Company Report

Pages: 4

Front-Line Setting Expansion Efforts Continue with FDA Submission of CASSIOPEIA Trial-Based Application; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 6

03/26/2019

Company Report

Pages: 4

EMA Application Submitted for DARZALEX''s Label Expansion in Transplant-Ineligible Multiple Myeloma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 7

03/13/2019

Company Report

Pages: 4

RTOR Pathway Could Expedite DARZALEX Approval in Transplant-Ineligible Multiple Myeloma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 8

03/04/2019

Company Report

Pages: 4

Genmab''s Pipeline Advances; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 9

02/26/2019

Company Report

Pages: 4

Phase 3 COLUMBA Trial Meets Co-Primary Endpoints, According to Expectations; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 10

02/21/2019

Company Report

Pages: 4

FY2018 Financial Results Reported; Continued Bullish Outlook for DARZALEX; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 11

02/13/2019

Company Report

Pages: 4

DARZALEX Split Dosing Regimen Approved - COLUMBA Trial Should Provide Differentiation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 12

02/06/2019

Company Report

Pages: 4

We Remain Confident on DARZALEX as Competition Heats Up; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 13

01/28/2019

Company Report

Pages: 4

MorphoSys Patents Declared Invalid; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 14

01/25/2019

Company Report

Pages: 5

DARZALEX Reach Slated to Broaden; Modulating Near-Term Estimates; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 15

12/10/2018

Company Report

Pages: 5

ASH Data Reinforces DARZALEX''s Front-Line Position in Multiple Myeloma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 16

11/13/2018

Company Report

Pages: 4

GEN1046 and GEN1042 SITC Posters Highlight Diverse Portfolio; DARZALEX Outlook Positive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 17

10/30/2018

Company Report

Pages: 5

Dexamethasone Emerges as New 1L Standard of Care; Reiterate Buy.

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 18

10/17/2018

Company Report

Pages: 5

Steady 3Q18 WW DARZALEX Sales Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 19

10/09/2018

Company Report

Pages: 4

Tisotumab Vedotin Remains an Underappreciated Asset; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Genmab A/S

Industry: Medical - Biomedical and Genetics

Record: 20

10/01/2018

Company Report

Pages: 35

Driven by DARZALEX; Initiating at Buy and DKK 1,600 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 75.00

Research Provided by a Third Party